New hope for rare bile duct cancer: tracking first Real-World results of approved targeted drug

NCT ID NCT06607302

Recruiting now Disease control Sponsor: iOMEDICO AG Source: ClinicalTrials.gov ↗

Summary

This study is collecting real-world information on how well the targeted drug ivosidenib works for people with advanced bile duct cancer who have a specific genetic mutation (IDH1 R132) and have already tried at least one other treatment. Researchers will follow 100 patients in Germany who are already receiving this approved medication to track how long the treatment keeps the cancer from growing, overall survival, side effects, and quality of life. The goal is to understand how the drug performs in everyday medical practice outside of controlled clinical trials.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Caritas Krankenhaus Bad Mergentheim
RECRUITING

Bad Mergentheim, Germany

Contact
Hämatologisch-Onkologische Schwerpunktpraxis in Bad Liebenwerda
RECRUITING

Bad Liebenwerda, Germany

Contact
Medizinisches Versorgungszentrum Mönchengladbach
RECRUITING

Mönchengladbach, Germany

Contact
Onkologie Hannover
RECRUITING

Hanover, Germany

Contact
Onkologie Hof
RECRUITING

Hof, Germany

Contact
Onkologisches Versorgungszentrum Berlin MVZ
RECRUITING

Berlin, Germany

Contact
ze:roPRAXEN MVZ für Innere Medizin
RECRUITING

Weinheim, Germany

Contact

Conditions

Explore the condition pages connected to this study.

CHOLANGIOCARCINOMA